Author:
Luetkemeyer Anne F.,Firnhaber Cynthia,Kendall Michelle A.,Wu Xingye,Mazurek Gerald H.,Benator Debra A.,Arduino Roberto,Fernandez Michel,Guy Elizabeth,Johnson Pamela,Metchock Beverly,Sattler Fred,Telzak Edward,Wang Yun F.,Weiner Marc,Swindells Susan,Sanne Ian M.,Havlir Diane V.,Grinsztejn Beatriz,Alland David
Funder
National Institute of Allergy and Infectious Diseases
ACTG
the CDC
the TBTC and the Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention
National Institute of Mental Health
National Institute of Dental and Craniofacial Research
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference18 articles.
1. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
2. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. Geneva, Switzerland: WHO, 2011.
3. US Food and Drug Administration. FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362602.htm . Accessed 1 December 2015.
4. US Food and Drug Administration. New data shows test can help physicians remove patients with suspected TB from isolation earlier. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm . Accessed 12 February 2015.
5. Bevilaqua AA . Boletim tuberculose 2014 [in Portugese]. Available at: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=wXJ%2BKouHyII%3D . Accessed 28 August 2015.